2.51
+0.40%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About JW (Cayman) Therapeutics Co
Its shares trade on HKEX under the ticker 2126.HK. It has been listed since 3 November 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥276.3m and a net loss of CN¥540.9m. At that date it held total assets of CN¥987.3m and shareholders' equity of CN¥556.5m.
JW (Cayman) Therapeutics Co. Ltd. engages in the research and development, manufacturing, and marketing of anti-tumor drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Nov 2020
- Employees
- 490
- Website
- jwtherapeutics.com ↗
Leadership
Pay as last reported
- Mr. Min LiuExecutive Chairman of the Board, Chief Executive Officer, since 2024
- Dr. Shau CordobaSenior Vice President, Chief Scientific Officer
- Mr. Raymond HageSenior Vice President
- Mr. Wu QiongChief Compliance Officer
- Ms. Ka Man NgJoint Company Secretary
- Dr. Liu ChengNon-Executive DirectorCN¥331,000
- Mr. SungWon SongNon-Executive Director
- Ms. Gao XingNon-Executive Director
- Mr. Kin Cheong HoNon-Executive Independent DirectorCN¥224,000
- Mr. Kuan Chan PengNon-Executive Independent Director
- Dr. Debra YuNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- JW (Cayman) Therapeutics employs 490 full-time staff in Shanghai to support its operations.
- The company has built an integrated platform for developing cell-based immunotherapies.
- Relmacabtagene autoleucel is a main product candidate targeting relapsed B-cell lymphoma.
Weaknesses
- The firm focuses primarily on the China market for its business activities.
- Relmacabtagene autoleucel is currently a product candidate rather than an approved drug.
- The company went public on 3 November 2020, which is a recent listing date.
Opportunities
- The company aims to transform cancer treatment for Chinese patients through cell therapies.
- JW (Cayman) Therapeutics develops therapies for hematological cancers and solid tumors.
- The integrated platform supports manufacturing and commercializing breakthrough cell-based immunotherapies.
Threats
- The company operates in the competitive biotechnology sector within the Health Care industry.
- Relmacabtagene autoleucel targets a specific patient population with relapsed or refractory conditions.
- The firm relies on its subsidiary to conduct research and development activities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.